Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 253

1.

Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group.

Roberts KG, Reshmi SC, Harvey RC, Chen IM, Patel K, Stonerock E, Jenkins H, Dai Y, Valentine M, Gu Z, Zhao Y, Zhang J, Payne-Turner D, Devidas M, Heerema NA, Carroll AJ, Raetz EA, Borowitz MJ, Wood BL, Mattano LA Jr, Maloney KW, Carroll WL, Loh ML, Willman CL, Gastier-Foster JM, Mullighan CG, Hunger SP.

Blood. 2018 Jul 11. pii: blood-2018-04-841676. doi: 10.1182/blood-2018-04-841676. [Epub ahead of print]

PMID:
29997224
2.

ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition.

Roberts KG, Janke LJ, Zhao Y, Seth A, Ma J, Finkelstein D, Smith S, Ebata K, Tuch BB, Hunger SP, Mullighan CG.

Blood. 2018 Jun 7. pii: blood-2018-05-849554. doi: 10.1182/blood-2018-05-849554. [Epub ahead of print] No abstract available.

PMID:
29880614
3.

Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.

Slayton WB, Schultz KR, Kairalla JA, Devidas M, Mi X, Pulsipher MA, Chang BH, Mullighan C, Iacobucci I, Silverman LB, Borowitz MJ, Carroll AJ, Heerema NA, Gastier-Foster JM, Wood BL, Mizrahy SL, Merchant T, Brown VI, Sieger L, Siegel MJ, Raetz EA, Winick NJ, Loh ML, Carroll WL, Hunger SP.

J Clin Oncol. 2018 Aug 1;36(22):2306-2314. doi: 10.1200/JCO.2017.76.7228. Epub 2018 May 29.

PMID:
29812996
4.

Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure.

Ding YY, Stern JW, Jubelirer TF, Wertheim GB, Li F, Chang F, Gu Z, Mullighan CG, Li Y, Harvey RC, Chen IM, Willman CL, Hunger SP, Li MM, Tasian SK.

Haematologica. 2018 May 17. pii: haematol.2018.192088. doi: 10.3324/haematol.2018.192088. [Epub ahead of print] No abstract available.

5.

High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-ALL.

Perez DR, Nickl CK, Waller A, Delgado-Martin C, Woods T, Sharma ND, Hermiston ML, Loh ML, Hunger SP, Winter SS, Chigaev A, Edwards B, Sklar LA, Matlawska-Wasowska K.

SLAS Discov. 2018 Aug;23(7):732-741. doi: 10.1177/2472555218774248. Epub 2018 May 10.

PMID:
29746793
6.

Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia.

Churchman ML, Qian M, Te Kronnie G, Zhang R, Yang W, Zhang H, Lana T, Tedrick P, Baskin R, Verbist K, Peters JL, Devidas M, Larsen E, Moore IM, Gu Z, Qu C, Yoshihara H, Porter SN, Pruett-Miller SM, Wu G, Raetz E, Martin PL, Bowman WP, Winick N, Mardis E, Fulton R, Stanulla M, Evans WE, Relling MV, Pui CH, Hunger SP, Loh ML, Handgretinger R, Nichols KE, Yang JJ, Mullighan CG.

Cancer Cell. 2018 May 14;33(5):937-948.e8. doi: 10.1016/j.ccell.2018.03.021. Epub 2018 Apr 19.

PMID:
29681510
7.

Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia.

Burns MA, Liao ZW, Yamagata N, Pouliot GP, Stevenson KE, Neuberg DS, Thorner AR, Ducar M, Silverman EA, Hunger SP, Loh ML, Winter SS, Dunsmore KP, Wood B, Devidas M, Harris MH, Silverman LB, Sallan SE, Gutierrez A.

Leukemia. 2018 Mar 20. doi: 10.1038/s41375-018-0097-x. [Epub ahead of print]

PMID:
29654263
8.

Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours.

Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, Zhou X, Li Y, Rusch MC, Easton J, Huether R, Gonzalez-Pena V, Wilkinson MR, Hermida LC, Davis S, Sioson E, Pounds S, Cao X, Ries RE, Wang Z, Chen X, Dong L, Diskin SJ, Smith MA, Guidry Auvil JM, Meltzer PS, Lau CC, Perlman EJ, Maris JM, Meshinchi S, Hunger SP, Gerhard DS, Zhang J.

Nature. 2018 Mar 15;555(7696):371-376. doi: 10.1038/nature25795. Epub 2018 Feb 28.

PMID:
29489755
9.

Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG).

Gupta S, Devidas M, Loh ML, Raetz EA, Chen S, Wang C, Brown P, Carroll AJ, Heerema NA, Gastier-Foster JM, Dunsmore KP, Larsen EC, Maloney KW, Mattano LA Jr, Winter SS, Winick NJ, Carroll WL, Hunger SP, Borowitz MJ, Wood BL.

Leukemia. 2018 Jun;32(6):1370-1379. doi: 10.1038/s41375-018-0039-7. Epub 2018 Feb 23.

PMID:
29472723
10.

MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia.

Evensen NA, Madhusoodhan PP, Meyer J, Saliba J, Chowdhury A, Araten DJ, Nersting J, Bhatla T, Vincent TL, Teachey D, Hunger SP, Yang J, Schmiegelow K, Carroll WL.

Haematologica. 2018 May;103(5):830-839. doi: 10.3324/haematol.2017.176362. Epub 2018 Feb 15.

11.

The ASPHO 2018 Distinguished Career Award goes to Dr. Michael P. Link.

Carroll WL, Hunger SP.

Pediatr Blood Cancer. 2018 Jun;65 Suppl 1:e26987. doi: 10.1002/pbc.26987. Epub 2018 Jan 31. No abstract available.

PMID:
29384264
12.

Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.

Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, Carson R, Dai Y, Devidas M, Dunsmore KP, Fuller T, Glisovic-Aplenc T, Horton TM, Hunger SP, Loh ML, Maude SL, Raetz EA, Winter SS, Grupp SA, Hermiston ML, Wood BL, Teachey DT.

Blood. 2018 Mar 1;131(9):995-999. doi: 10.1182/blood-2017-07-794214. Epub 2018 Jan 5.

PMID:
29305553
13.

TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children.

Qian M, Cao X, Devidas M, Yang W, Cheng C, Dai Y, Carroll A, Heerema NA, Zhang H, Moriyama T, Gastier-Foster JM, Xu H, Raetz E, Larsen E, Winick N, Bowman WP, Martin PL, Mardis ER, Fulton R, Zambetti G, Borowitz M, Wood B, Nichols KE, Carroll WL, Pui CH, Mullighan CG, Evans WE, Hunger SP, Relling MV, Loh ML, Yang JJ.

J Clin Oncol. 2018 Feb 20;36(6):591-599. doi: 10.1200/JCO.2017.75.5215. Epub 2018 Jan 4.

14.

A framework to develop adapted treatment regimens to manage pediatric cancer in low- and middle-income countries: The Pediatric Oncology in Developing Countries (PODC) Committee of the International Pediatric Oncology Society (SIOP).

Howard SC, Davidson A, Luna-Fineman S, Israels T, Chantada G, Lam CG, Hunger SP, Bailey S, Ribeiro RC, Arora RS, Pedrosa F, Harif M, Metzger ML.

Pediatr Blood Cancer. 2017 Dec;64 Suppl 5. doi: 10.1002/pbc.26879.

PMID:
29297619
15.

Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL.

Roberts KG, Yang YL, Payne-Turner D, Lin W, Files JK, Dickerson K, Gu Z, Taunton J, Janke LJ, Chen T, Loh ML, Hunger SP, Mullighan CG.

Blood Adv. 2017 Aug 30;1(20):1657-1671. doi: 10.1182/bloodadvances.2017011296. eCollection 2017 Sep 12.

16.

Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study.

Barredo JC, Hastings C, Lu X, Devidas M, Chen Y, Armstrong D, Winick N, Wood BL, Yanofsky R, Loh M, Gastier-Foster JM, Jorstad DT, Marcus R, Ritchey K, Carrol WL, Hunger SP.

Pediatr Blood Cancer. 2018 May;65(5):e26928. doi: 10.1002/pbc.26928. Epub 2017 Dec 29.

PMID:
29286562
17.

Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL.

Wood B, Wu D, Crossley B, Dai Y, Williamson D, Gawad C, Borowitz MJ, Devidas M, Maloney KW, Larsen E, Winick N, Raetz E, Carroll WL, Hunger SP, Loh ML, Robins H, Kirsch I.

Blood. 2018 Mar 22;131(12):1350-1359. doi: 10.1182/blood-2017-09-806521. Epub 2017 Dec 28.

18.

Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232.

DiNofia AM, Seif AE, Devidas M, Li Y, Hall M, Huang YV, Cahen V, Hunger SP, Winick NJ, Carroll WL, Fisher BT, Larsen EC, Aplenc R.

Cancer Med. 2018 Jan;7(1):3-12. doi: 10.1002/cam4.1206. Epub 2017 Dec 23.

19.

Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131.

Salzer WL, Burke MJ, Devidas M, Chen S, Gore L, Larsen EC, Borowitz M, Wood B, Heerema NA, Carroll AJ, Hilden JM, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP.

Cancer. 2018 Mar 15;124(6):1150-1159. doi: 10.1002/cncr.31099. Epub 2017 Dec 19.

PMID:
29266189
20.

Acute lymphoblastic leukaemia in 2017: Immunotherapy for ALL takes the world by storm.

Teachey DT, Hunger SP.

Nat Rev Clin Oncol. 2018 Feb;15(2):69-70. doi: 10.1038/nrclinonc.2017.176. Epub 2017 Dec 19. No abstract available.

PMID:
29255238

Supplemental Content

Loading ...
Support Center